Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s activity neared its end, after the company announced its third-quarter 2024 financial results and outlook for the rest of the year.
Net sales rose by 1.8% to 5.27 billion euros ($5.57) compared to the same period in 2023, while earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for special items, were 1.62 billion euros, a jump of 11.8% and ahead of an average analyst estimate of 1.55 billion euros in a consensus posted on the company’s website.
Merck, which previously predicted 2024 sales of between 20.7 billion euros and 22.1 billion euros, said it now expects its revenue to be in the lower half of that range. Full-year adjusted EBITDA is now predicted to be around the mid-point of its target range of 5.8 billion to 6.4 billion euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze